Advertisement
UK markets close in 6 hours 5 minutes

  • FTSE 100

    8,047.58
    +23.71 (+0.30%)
     

  • FTSE 250

    19,676.60
    +77.21 (+0.39%)
     

  • AIM

    751.70
    +2.52 (+0.34%)
     

  • GBP/EUR

    1.1596
    +0.0007 (+0.06%)
     

  • GBP/USD

    1.2365
    +0.0015 (+0.12%)
     

  • Bitcoin GBP

    53,538.40
    +161.14 (+0.30%)
     

  • CMC Crypto 200

    1,395.86
    -18.90 (-1.34%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.28
    +0.38 (+0.46%)
     

  • GOLD FUTURES

    2,310.70
    -35.70 (-1.52%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    17,961.54
    +100.74 (+0.56%)
     

  • CAC 40

    8,067.81
    +27.45 (+0.34%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Verastem Oncology to Participate in Upcoming Investor Conferences

Business Wire
·1-min read

BOSTON, May 01, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

  • JMP Securities Life Sciences Conference; podium presentation on Tuesday, May 16, 2023 at 1:00 p.m. ET

  • RBC Capital Markets Global Healthcare Conference; fireside chat on Wednesday, May 17, 2023 at 2:05 p.m. ET

A live webcast of the presentation and fireside chat will be available on the investors section of the Company’s website at www.verastem.com. An archived replay of the presentation and fireside chat will be made available on the same website for approximately 90 days following each event.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005068/en/

Contacts

Investors:
Dan Calkins
+1 781-469-1694
dcalkins@verastem.com

Nate LiaBraaten
+1 212-600-1902
nate@argotpartners.com

Media:
Lisa Buffington
+1 (781) 292-4205
lbuffington@verastem.com